ArticleMalaria journal2017
In vitro activity of anti-malarial ozonides against an artemisinin-resistant isolate.
Article in Malaria journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Double Mutations inbioRxiv : the preprint server for biology · 2026Article
- Article
- Targeting Malaria's Achilles' Heels: A Review of Plasmodium Life Cycle Vulnerabilities for Drug Discovery.Current topics in medicinal chemistry · 2025Review
- Enhanced cell stress response and protein degradation capacity underlie artemisinin resistance inmSphere · 2024Article
- Traditional uses, Phytochemistry, Pharmacology, and Toxicology of the GenusCurrent topics in medicinal chemistry · 2024Review
- Parasite proteostasis and artemisinin resistance.Research square · 2023Article
- Artefenomel Regioisomer RLA-3107 Is a Promising Lead for the Discovery of Next-Generation Endoperoxide Antimalarials.ACS medicinal chemistry letters · 2023Article
- Naturally Acquired Kelch13 Mutations in Plasmodium falciparum Strains ModulateMicrobiology spectrum · 2022Article
- Peroxide Antimalarial Drugs Target Redox Homeostasis inACS infectious diseases · 2022Article
- Article
- Antimalarial Trioxolanes with Superior Drug-Like Properties and In Vivo Efficacy.ACS infectious diseases · 2020Article
- System-wide biochemical analysis reveals ozonide antimalarials initially act by disrupting Plasmodium falciparum haemoglobin digestion.PLoS pathogens · 2020Article
- Anti-malarial ozonides OZ439 and OZ609 tested at clinically relevant compound exposure parameters in a novel ring-stage survival assay.Malaria journal · 2019Article
- Two successful decades of Swiss collaborations to develop new anti-malarials.Malaria journal · 2019Article
- How to combat emerging artemisinin resistance: Lessons from "The Three Little Pigs".PLoS pathogens · 2018Article
- Parasite-Mediated Degradation of Synthetic Ozonide Antimalarials ImpactsAntimicrobial agents and chemotherapy · 2018Article
- Tackling resistance: emerging antimalarials and new parasite targets in the era of elimination.F1000Research · 2018Review
- Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic.Nature medicine · 2017Review
- Enantioselective Synthesis and in Vivo Evaluation of Regioisomeric Analogues of the Antimalarial Arterolane.Journal of medicinal chemistry · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecently published data suggest that artemisinin derivatives and synthetic peroxides, such as the ozonides OZ277 and OZ439, have a similar mode of action. Here the cross-resistance of OZ277 and OZ439 and four additional next-generation ozonides was probed against the artemisinin-resistant clinical isolate Plasmodium falciparum Cam3.I, which carries the K13-propeller mutation R539T (Cam3.I
methodsThe previously described in vitro ring-stage survival assay (RSA
resultsAt the pharmacologically relevant concentration of 700 nM, all six ozonides were highly effective against the dihydroartemisinin-resistant P. falciparum Cam3.I
conclusionThe absence of in vitro cross-resistance against the artemisinin-resistant clinical isolate Cam3.I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.